18 completed. 18 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 18 | Completed 18 |
Follow Corticosteroids: new trials by email Literature Review of Corticosteroids trials Research Report on Corticosteroids
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients Tacrolimus immediate-release formulation, Tacrolimus prolonged-release formulation, Induction therapy - Kidney Transplant | Phase 4 | Completed | Astellas Pharma China, Inc. | 284 | 2018-10-21 | 2024-10-31 |
| Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients Tacrolimus Extended Release Capsule, Mycophenolate mofetil, Prednisone - Immunosuppression | Phase 4 | Completed | Medical University of South Carolina | 25 | 2017-05-05 | 2019-12-26 |
| SCHEDULE Follow Up Visit 5-7 yr Everolimus, Cyclosporine, Mycophenolate mofetil - Heart Transplantation | Phase 4 | Completed | Novartis Pharmaceuticals | 95 | 2016-01-18 | 2019-10-03 |
| Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) Induction therapy, Corticosteroids, EVR+rCNI - End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD) | Phase 4 | Completed | Novartis Pharmaceuticals | 2037 | 2013-12-03 | 2019-01-30 |
| Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients Everolimus, Tacrolimus, Corticosteroids - Liver Transplantation | Phase 4 | Completed | Novartis Pharmaceuticals | 339 | 2012-05-24 | 2019-05-10 |
| A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus. Advagraf, Mycophenolate Mofetil, Sirolimus - Kidney Transplantation | Phase 4 | Completed | Astellas Pharma Inc | 853 | 2011-03-08 | 2024-10-31 |
| A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids Advagraf, Mycophenolate Mofetil, Simulect - Kidney Transplantation | Phase 4 | Completed | Astellas Pharma Inc | 1166 | 2011-01-22 | 2024-11-01 |
| Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients Everolimus, Tacrolimus (FK506), Basiliximab - Chronic Renal Failure | Phase 4 | Completed | Novartis Pharmaceuticals | 36 | 2009-12-01 | 2014-08-15 |
| SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance Cyclosporine, Mycophenolate mofetil, Corticosteroids - Renal Function and Chronic Allograft Vasculopathy | Phase 4 | Completed | Novartis Pharmaceuticals | 115 | 2009-11-01 | 2015-06-10 |
| A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients Everolimus (EVR), cyclosporine A (CyA), tacrolimus (TAC) - Heart Transplantation | Phase 4 | Completed | Novartis Pharmaceuticals | 162 | 2009-02-24 | 2018-08-07 |
| A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients. mycophenolate mofetil, tacrolimus, standard dose, tacrolimus, low dose - Kidney Transplantation | Phase 4 | Completed | Hoffmann-La Roche | 210 | 2008-09-01 | 2014-08-04 |
| A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection Prograf®, Advagraf®, Mycophenolate Mofetil - Kidney Transplantation | Phase 4 | Completed | Astellas Pharma Inc | 1252 | 2008-05-14 | 2024-11-01 |
| Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients everolimus, cyclosporine A, Enteric Coated Mycophenolate Sodium (EC-MPS) - Renal Function | Phase 4 | Completed | Novartis Pharmaceuticals | 204 | 2008-03-01 | 2014-08-13 |
| A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients Everolimus (RAD001), Tacrolimus, Basiliximab - Renal Transplantation | Phase 4 | Completed | Novartis | 228 | 2006-06-01 | 2017-03-03 |
| Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids basiliximab, MMF/EC-MPS, Corticosteroids - Kidney Transplantation, Adverse Effects | Phase 4 | Completed | Novartis | 7 | 2006-01-01 | 2017-03-29 |
| Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients Everolimus, Cyclosporine, Enteric-coated mycophenolate sodium - Renal Transplantation | Phase 4 | Completed | Novartis | 300 | 2005-06-01 | 2013-11-13 |
| Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients mycophenolate mofetil [CellCept], Corticosteroids, Calcineurin inhibitors - Kidney Transplantation | Phase 4 | Completed | Hoffmann-La Roche | 305 | 2003-08-01 | 2011-04-15 |
| Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus Rapamune® (Sirolimus), Neoral® (Cyclosporine), Corticosteroids - Kidney Transplantation | Phase 4 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 250 | 2000-04-01 | 2023-12-11 |
Kidney Failure, Chronic (2) · Acute Kidney Injury (1) · Diabetes Mellitus (1) · Graft vs Host Disease (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
Novartis Pharmaceuticals (7) · Astellas Pharma Inc (3) · Novartis (3) · Hoffmann-La Roche (2) · Astellas Pharma China, Inc. (1) · Medical University of South Carolina (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
Germany (7) · Norway (6) · Sweden (6) · Switzerland (6) · Belgium (4) · Czechia (4) · France (4) · Italy (4) · Netherlands (4) · Poland (4) · Russia (4) · Spain (4) · Australia (3) · Austria (3) · Denmark (3)
PMID 21334736, PMID 22471345, PMID 25041227, PMID 25070687, PMID 25873064, PMID 26820618, PMID 27547871, PMID 28230646, PMID 29149958, PMID 29752413, PMID 29954336, PMID 30211826, PMID 30231851, PMID 30312541, PMID 30354362, PMID 31152476, PMID 32633157, PMID 34216395, PMID 34525259, PMID 34620664, PMID 40197799, PMID 42853965
2009 (1), 2016 (1)